1. Montalban, X, Hauser, SL, Kappos, L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376: 209–220.
Google Scholar | Crossref | Medline | ISI2. Kappos, L, Bar-Or, A, Cree, BAC, et al. EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet 2018; 391(10127): 1263–1273.
Google Scholar | Crossref | Medline3. Absinta, M, Lassmann, H, Trapp, BD. Mechanisms underlying progression in multiple sclerosis. Curr Opin Neurol 2020; 33(3): 277–285.
Google Scholar | Crossref | Medline4. Barbour, C, Kosa, P, Komori, M, et al. Molecular-based diagnosis of multiple sclerosis and its progressive stage. Ann Neurol 2017; 82(5): 795–812.
Google Scholar | Crossref | Medline5. Cree, BAC, Cutter, G, Wolinsky, JS, et al. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2020; 19(12): 988–997.
Google Scholar | Crossref | Medline6. Fox, RJ, Coffey, CS, Conwit, R, et al. Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med 2018; 379(9): 846–855.
Google Scholar | Crossref | Medline7. Lublin, FD, Reingold, SC, Cohen, JA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014; 83(3): 278–286.
Google Scholar | Crossref | Medline | ISI8. Khaleeli, Z, Ciccarelli, O, Mizskiel, K, et al. Lesion enhancement diminishes with time in primary progressive multiple sclerosis. Mult Scler 2010; 16(3): 317–324.
Google Scholar | SAGE Journals | ISI9. Benedict, RHB, Tomic, D, Cree, BAC, et al. Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses. Neurology 2021; 96(3): e376–e386.
Google Scholar | Crossref | Medline10. Sellebjerg, F, Bornsen, L, Ammitzbell, C, et al. Defining active progressive multiple sclerosis. Mult Scler 2017; 23(13): 1727–1735.
Google Scholar | SAGE Journals | ISI